Document is current
Any future updates will be listed below
-
Authors
Teshale, Achamyeleh Birhanu https://orcid.org/0000-0002-7572-9993
Htun, Htet Lin https://orcid.org/0000-0003-2307-0610
Owen, Alice J. https://orcid.org/0000-0002-4807-6069
Baker, JR https://orcid.org/0000-0002-8290-3996
Isaksen, Irja https://orcid.org/0009-0005-8094-1349
Freak-Poli, Rosanne https://orcid.org/0000-0003-4072-8699
-
Funding
Funding for this research was provided by:
National Institute on Aging and the National Cancer Institute at the U.S. National Institutes of Health (U01AG029824, U19AG062682)
National Health and Medical Research Council of Australia (334047, 1127060)
Victorian Cancer Agency
Monash University
ANZ Trustees, the Wicking Trust, and the Mason Foundation
Monash International Tuition Scholarship and the Monash Graduate Scholarship
Monash University
- License Information
-
More Information
Article History
Received: 20 January 2025
Accepted: 2 June 2025
First Online: 25 June 2025
Declarations:
:
: The ASPREE trial and ALSOP sub-study adhered to the ethical principles outlined in the Declaration of Helsinki 1964, as revised in 2008. The ASPREE trial received approval from multiple Institutional Review Boards in both Australia and the USA (). Similarly, the ALSOP sub-study was reviewed and approved by the Monash University Human Research Ethics Committee (Social ALSOP: CF11/1935–2011001094). All participants provided informed consent to partake in the ASPREE clinical trial and ALSOP sub-study. Furthermore, the present study was approved by the Monash University Human Research Ethics Committee to conduct secondary data analysis (project ID: 35233).
: The authors have no conflict of interest to declare.
